Goldman and Jena Discuss the Challenges of Value-Based Pricing in STAT News

In a new commentary for STAT News, PHE co-founder Dana Goldman and scientific advisor Anupam Jena discuss the advantages of value-based pricing, pointing out several of the key challenges that complicate the application of health technology assessments. Goldman and Jena make the case that more transparency is needed and that an open-source model would allow underlying assumptions to be assessed, criticized and modified by all stakeholders.

To read the complete article, please click here.

Precision Medicine Group is an integrated team of experts in fields from advanced lab sciences to translational informatics and regulatory affairs, payer insights to marketing communications. Together, we help our pharmaceutical and life-sciences clients conquer product development and commercialization challenges in a rapidly evolving environment.